company background image
CLVS.Q logo

Clovis Oncology OTCPK:CLVS.Q Rapport sur les actions

Dernier prix

US$0.015

Capitalisation boursière

US$2.2m

7D

18.1%

1Y

-99.4%

Mise à jour

12 Jul, 2023

Données

Finances de l'entreprise

Clovis Oncology, Inc.

OTCPK:CLVS.Q Rapport sur les actions

Capitalisation boursière : US$2.2m

CLVS.Q Aperçu des actions

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.

CLVS.Q analyse fondamentale
Score flocon de neige
Évaluation2/6
Croissance future0/6
Performances passées0/6
Santé financière0/6
Dividendes0/6

Clovis Oncology, Inc. Concurrents

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Clovis Oncology
Historique des cours de bourse
Prix actuel de l'actionUS$0.015
Plus haut sur 52 semainesUS$2.87
Plus bas sur 52 semainesUS$0.01
Bêta0.66
1Variation sur 1 mois-40.00%
Variation sur 3 mois-28.57%
Variation sur 1 an-99.39%
3Variation sur 3 ans-99.77%
Variation sur 5 ans-99.97%
Évolution depuis l'introduction en bourse-99.88%

Nouvelles et mises à jour récentes

Recent updates

Clovis Oncology rises on clinical supply agreement with Isotopia

Sep 21

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep 12

Clovis Oncology: Needs Some Encouraging Data Quickly

Aug 11

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Aug 10
These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Clovis Oncology Q2 2022 Earnings Preview

Aug 05

EMA recommends restricted use of Clovis cancer drug

Jul 22

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Jul 08

Clovis: Shifting Toward Nuclear Medicine

Apr 25

Clovis Oncology: Forging A Fresh Perspective

Mar 31

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Feb 24
News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Jan 11

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Dec 30

Clovis Oncology Stock: Only Glimmers Of Hope

Oct 07

Clovis: Compelling With Upcoming Catalysts

Jul 30

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Jun 17
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Clovis Oncology and Inovio gain amid Reddit chatter

Jun 09

Clovis Oncology: Another Upcycle Coming

May 08

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

May 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Mar 17
Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 22
How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Jan 31

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Jan 29

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

Jan 11

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Dec 31
What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Dec 29

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study

Dec 21

Clovis Oncology existing holder purchases additional $7.5M convertible senior notes

Nov 25

Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance

Nov 09

Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term

Nov 06

Clovis Oncology EPS beats by $0.11, misses on revenue

Nov 05

Rendement pour les actionnaires

CLVS.QUS BiotechsUS Marché
7D18.1%-1.3%-1.6%
1Y-99.4%19.1%30.1%

Rendement vs Industrie: CLVS.Q a sous-performé le secteur US Biotechs qui a rapporté 19.1 % au cours de l'année écoulée.

Rendement vs marché: CLVS.Q a sous-performé le marché US qui a rapporté 30.1 % au cours de l'année écoulée.

Volatilité des prix

Is CLVS.Q's price volatile compared to industry and market?
CLVS.Q volatility
CLVS.Q Average Weekly Movement61.3%
Biotechs Industry Average Movement9.6%
Market Average Movement6.1%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market3.0%

Cours de l'action stable: Le cours de l'action de CLVS.Q a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de CLVS.Q est passée de 39% à 61% au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
2009413Patrick Mahaffywww.clovisoncology.com

Clovis Oncology, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Clovis Oncology se comparent-ils à sa capitalisation boursière ?
CLVS.Q statistiques fondamentales
Capitalisation boursièreUS$2.18m
Bénéfices(TTM)-US$251.91m
Recettes(TTM)US$133.02m

0.0x

Ratio P/S

0.0x

Ratio P/E

Le site CLVS.Q est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
CLVS.Q compte de résultat (TTM)
RecettesUS$133.02m
Coût des recettesUS$31.59m
Marge bruteUS$101.43m
Autres dépensesUS$353.33m
Les revenus-US$251.91m

Derniers bénéfices déclarés

Sep 30, 2022

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-1.73
Marge brute76.25%
Marge bénéficiaire nette-189.37%
Ratio dettes/capitaux propres-158.0%

Quelles ont été les performances à long terme de CLVS.Q?

Voir les performances historiques et les comparaisons